GPT-Rosalind (OpenAI)
C Tier · 6.8/10
OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)
Score Breakdown
The Good and the Bad
What we like
- +OpenAI's first named vertical/domain-specific model -- signals a new strategy beyond general-purpose GPT-5.x. The pattern (vertical + gated rollout + blue-chip launch partners) echoes the 2026-04-07 Anthropic Mythos Preview / Project Glasswing model and suggests how frontier-lab productization will work in 2026 and beyond
- +Launch partners Amgen, Moderna, Allen Institute, Thermo Fisher are credible biotech and research institutions -- not just splashy logos. Suggests the model has been meaningfully trained/tuned on real biology data with real domain expertise in the loop
- +Life Sciences Codex plugin is the practical hook -- 50+ scientific tool integrations (PubMed, BioRxiv, UniProt, scientific Python libraries) mean Codex can now run multi-step research workflows: literature search, protein lookup, reagent ordering scripts, experimental design in one chain
- +OpenAI is now playing in the space Anthropic's Mythos targets (gated domain models) with Nvidia's vertical strategy (BioNeMo, Evo) and Google's Med-PaLM lineage. Competition drives rapid improvement
What could be better
- −Not available to anyone reading this unless your org is already a Trusted Access partner. If you are at Amgen or Moderna, ask internally. Everyone else: wait and see
- −Domain-specific model, so for general-purpose work Opus 4.7, GPT-5.4, or Gemini 3.1 Pro remain the right answer -- GPT-Rosalind will be narrower in scope even once broadly available
- −Trusted Access means OpenAI controls who uses it. Unlike consumer ChatGPT, there is no path from 'I am curious' to 'I am using it' without an enterprise sales conversation
- −Claims need third-party verification. At launch, OpenAI has not published open benchmarks. Expect published drug-discovery / biology evals from neutral sources over next 3-6 months
Pricing
Trusted Access (gated)
- ✓Research preview limited to partner organizations
- ✓Launch partners: Amgen, Moderna, Allen Institute for Cell Science, Thermo Fisher
- ✓Application required via OpenAI enterprise sales
- ✓Not available to consumer ChatGPT users
Life Sciences Codex Plugin
- ✓50+ scientific tool integrations (PubMed, BioRxiv, UniProt, etc.)
- ✓Works with Codex cloud agent for multi-step research workflows
- ✓Available in ChatGPT Pro ($100/mo) and Business tiers
Public access
- ✓Not being released publicly as a standalone product
- ✓Consumer use case unclear -- this is an enterprise / research tool
Known Issues
- Trusted Access rollout -- not open for self-serve signup. Launched 2026-04-16 with fewer than 10 named partners. Broader access timeline not announcedSource: OpenAI launch post · 2026-04
- No independently-published benchmark results yet. OpenAI's claims (life-science reasoning superiority over general-purpose GPT-5.x) rely on internal evaluations. Wait for neutral published comparisons over Q2/Q3 2026Source: VentureBeat, OpenAI launch coverage · 2026-04
Best for
Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.
Not for
General-purpose use (use GPT-5.4, Opus 4.7, or Gemini 3.1 Pro). Consumer users who are not in a partner org (no access available). Anyone expecting standalone consumer pricing -- this is an enterprise / research play only.
Our Verdict
GPT-Rosalind is OpenAI's first named vertical model, launched 2026-04-16 as a Trusted Access preview with Amgen, Moderna, Allen Institute, and Thermo Fisher as launch partners. The parallel to Anthropic's Mythos Preview (2026-04-07) is clear: frontier labs are shipping gated domain-specific models while keeping their general-purpose models (GPT-5.x, Opus 4.x) publicly accessible. For life-sciences researchers in those partner orgs, this is a real capability upgrade worth exploring. For everyone else, it is a strategic signal: expect GPT-[domain] models in law, finance, defense, and other verticals through 2026, and expect broad availability never to materialize for the most capable tiers. The bundled Life Sciences Codex plugin (50+ scientific tool integrations) is the more immediately actionable item -- ChatGPT Pro and Business users can run multi-step life-sciences research workflows with it starting today.
Sources
- OpenAI: Introducing GPT-Rosalind (accessed 2026-04-17)
- VentureBeat: OpenAI debuts GPT-Rosalind + Codex plugin (accessed 2026-04-17)
- Industry analysis of vertical AI strategy (accessed 2026-04-17)
Alternatives to GPT-Rosalind (OpenAI)
Claude (Anthropic)
Anthropic's flagship LLM -- Opus 4.7 (launched April 16, 2026) with 1M-token context, high-res vision, new xhigh reasoning level, and the most natural conversational style
Claude Mythos Preview
Anthropic's most capable model -- a gated research preview via Project Glasswing, cybersecurity-specialized. 73% success on expert CTF tasks, 32-step autonomous network attacks. Not generally available.
Gemini (Google)
Google's LLM with deep Google Workspace integration, 2M token context window, and native code execution
Grok
xAI's irreverent chatbot with a direct line to X/Twitter -- real-time data meets unfiltered personality
Muse Spark (Meta)
Meta's first model from its Superintelligence Lab -- natively multimodal with Contemplating mode for multi-agent reasoning